Measles and rubella elimination country profile: Russian Federation

Measles elimination status Rubella elimination status Total population 143 989 754 < 1 year old 1 870 408 < 5 years old 9 527 025 Demographic information, 2017 Source: World Population Prospects: The 2017 Revision, New York, United Nations Measles and rubella surveillance National case-based surveillance for measles, rubella and CRS Lab confirmation for diagnosis of measles, rubella and CRS Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017 Measles and rubella elimination country profile Russian Federation Measles and rubella immunization schedule*, 2017 Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine * Measles vaccine provided to 18 to 55 year olds Measles and rubella cases and immunization coverage, 2008–2017 Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MCV1 = first dose of measles-containing vaccine MCV2= second dose of measles-containing vaccine Definition used for an outbreak Source: Measles and rubella elimination Annual Status Update report, 2017 and prior communication with the country Minimum two cases of measles or rubella including epidemiologically linked cases 2016 interrupted 2017 eliminated Confirmed measles cases by month of onset, 2013-2017 Source: CISID 2017 Vaccine Schedule MCV1 MMR 12 months MCV2 MMR 6 years Year of introduction MCV2 1987 RCV 2000 Measles vaccination in school Yes 2016 interrupted 2017 endemic 0 10 20 30 40 50 60 70 80 90 100 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 10000 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % co ve ra ge Nu m be r o f c as es Year Measles Rubella MCV1 coverage MCV2 coverage 0 200 400 600 800 1000 1200 1400 J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D 2013 2014 2015 2016 2017 N um be r of c as es Month and year Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc Measles and rubella elimination country profile Russian Federation ©WHO 2019 Information on CRS, 2017 No cases reported Source: Measles and rubella elimination Annual Status Update report, 2017 CRS = congenital rubella syndrome Measles cases by first subnational level, 2017 Source: Measles and rubella elimination Annual Status Update report, 2017 Measles genotypes by first subnational level, 2017 Source: MeaNS 2017 Note: The dots in the maps are placed randomly within the administrative regions. Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Sources of infection, 2017 Measles Rubella Imported 22 1 Import-related 481 4 Unknown/ Not reported 43 0 Endemic 175 0 Source: Measles and rubella elimination Annual Status Update report, 2017 Measles cases by age group and vaccination status, 2017 Source: Measles and rubella elimination Annual Status Update report, 2017 Note: Excludes imported cases Supplementary immunization activities Year Target age Vaccine used % Coverage 2017 18-55Y MCV 82.1-92.5% 2017 18-25Y RCV 42.4-92.4% Source: Supplementary immunization activities, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MCV = measles-containing vaccine; RCV = rubella-containing vaccine ND = Data not available 1dot=1case •B3 •D8 •H1 •D9 0 20 40 60 80 100 < 1 1-4 5-9 10-14 15-19 20-29 30 + % o f c as es Age group (years) 0 doses 1 dose 2 or more doses Unknown Suspected measles cases Confirmed measles cases Discarded as non- measles Measles incidence Genotypes detected Laboratory Epi- linked Clinically Total 2013 6297 2237 95 7 2339 3958 16.3 B3,D4,D8 2014 8856 4241 470 0 4711 4145 32.3 B3,D4,D8 2015 4192 804 39 0 843 3349 5.8 B3,D8,H1 2016 3306 173 5 0 178 3128 1.2 D8, H1 2017 4395 689 31 1 21 3674 4.9 B3,D8,H1 Measles incidence, epidemiologic and virologic characteristics, 2013-2017 Measles surveillance and laboratory performance indicators, 2013-2017 Source: Measles and rubella elimination Annual Status Update report, 2013-2017 Incidence calculated per 1 million population ND = Data not available; NA= Not applicable Source: ASU 2013-2017 and communication with the country ND = Data not available; NA= Not applicable A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory Rubella incidence, epidemiologic and virologic characteristics, 2013-2017 Rubella surveillance and laboratory performance indicators, 2013-2017 Source: Measles and rubella elimination Annual Status Update report, 2013-2017 Incidence calculated per 1 million population ND = Data not available; NA= Not applicable Source: ASU 2013-2017 and communication with the country ND = Data not available; NA= Not applicable A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory Surveillance performance indicators and targets a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population b. % cases with adequate laboratory investigation: ≥ 80% c. % origin of infection known: ≥ 80% d. Rate of viral detection: ≥ 80% Measles and rubella elimination country profile Russian Federation Discarded non- measles rate % 1st sub- national unit with ≥ 2 discarded cases % cases with adequate laboratory investigation % origin of infection known # specimen tested for measles % positive for measles Rate of viral detection % WHO and proficient labs 2013 2.8 68.7% 98.5% 100% 6463 34.9% 66% 100% 2014 2.8 100% 98.9% 100% 9162 48.3% 65.5% 100% 2015 2.3 100% 99.0% 100% 4727 18.1% 73.5% 100% 2016 2.1 100% 99.0% 100% 3772 6.1% 83.3% 100% 2017 2.5 84.2% 97.3% 94% 4364 18.5% 95.2% 100% Suspected rubella cases Confirmed rubella cases Discarded as non- rubella Rubella incidence Genotypes detected Laboratory Epi- linked Clinically Total 2013 5050 190 43 0 233 4817 1.6 2B 2014 5481 57 15 0 72 5409 0.5 2B, 1E 2015 3310 25 0 0 25 3285 0.2 2B 2016 3214 34 4 0 38 3176 0.3 2B 2017 4290 5 0 0 5 4285 0 1H Discarded non- rubella rate % 1st sub- national unit with ≥ 2 discarded cases % cases with adequate laboratory investigtion % origin of infection known # specimen tested for rubella % positive for rubella Rate of viral detection % WHO and proficient labs 2013 3.4 68.7% 98.5% 100% 4125 4.2% 12.5% 100% 2014 2.3 100% 98.9% 100% 5481 1.9% 100% 100% 2015 2.2 100% 99.0% 100% 4327 1.0% 100% 100% 2016 2.1 100% 99.0% 100% 3713 1.5% 33.3% 100% 2017 2.9 99.9% 97.2% 100% 4290 0.8% ND 100% RVC comments, based on 2017 reporting The Regional Verification Commission for Measles and Rubella Elimination (RVC) commends the national verification com- mittee for measles and rubella elimination (NVC), national health authorities and public health system on achieving rubella elimination. The RVC repeatedly commends a high quality of ASU, including comprehensive analysis and detailed laborato- ry information provided. The RVC agrees with the NVC conclusion that measles endemic transmission was re-established in 2017, and is looking forward to learn about activities and steps taken to address measles immunity challenges. ©WHO 2019 Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc